Crossmark

Efficacy and safety of camrelizumab combined with chemotherapy in the treatment of advanced biliary malignancy and associations between peripheral blood lymphocyte subsets and clinical outcomes

Crossref DOI link: https://doi.org/10.1007/s12094-024-03707-x

Published Online: 2024-09-18

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Zhao, Jian

Guo, Hongxing

Wu, Chenxuan https://orcid.org/0009-0007-9576-153X
Guo, Hongsheng
License Information

Text and Data Mining valid from 2024-09-18

Version of Record valid from 2024-09-18
More Information

Article History

Received: 22 June 2024

Accepted: 28 August 2024

First Online: 18 September 2024

Declarations

:

: The authors declare that they have no competing interests.

: This study has been approved by Institutional Ethics Committee of Tianjin Third Central Hospital (ethic code: IRB2019-010–01). Informed consent was obtained from all individual participants included in the study.

Document is current

Any future updates will be listed below